DE69930753D1 - Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu - Google Patents

Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu

Info

Publication number
DE69930753D1
DE69930753D1 DE69930753T DE69930753T DE69930753D1 DE 69930753 D1 DE69930753 D1 DE 69930753D1 DE 69930753 T DE69930753 T DE 69930753T DE 69930753 T DE69930753 T DE 69930753T DE 69930753 D1 DE69930753 D1 DE 69930753D1
Authority
DE
Germany
Prior art keywords
immune response
induction
polarised
response
cellular immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69930753T
Other languages
English (en)
Inventor
James Brayden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Application granted granted Critical
Publication of DE69930753D1 publication Critical patent/DE69930753D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
DE69930753T 1998-09-01 1999-08-31 Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu Expired - Lifetime DE69930753D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9876098P 1998-09-01 1998-09-01
PCT/IE1999/000087 WO2000012125A1 (en) 1998-09-01 1999-08-31 Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor

Publications (1)

Publication Number Publication Date
DE69930753D1 true DE69930753D1 (de) 2006-05-18

Family

ID=22270768

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930753T Expired - Lifetime DE69930753D1 (de) 1998-09-01 1999-08-31 Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu

Country Status (7)

Country Link
EP (1) EP1107783B1 (de)
JP (1) JP4526708B2 (de)
AT (1) ATE322285T1 (de)
AU (1) AU5441299A (de)
CA (2) CA2731995C (de)
DE (1) DE69930753D1 (de)
WO (1) WO2000012125A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59409668D1 (de) 1993-12-23 2001-04-05 Bruno Gander Mit Antigen beladene Mikropartikel und pharmazeutische Zubereitungen, die diese Mikropartikel enthalten.
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
EP1429749A2 (de) 2001-09-26 2004-06-23 Baxter International Inc. Herstellung von nanopartikeln im submikrometerbereich durch dispersion und entzug des lösungsmittels oder der flüssigen phase
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP4851067B2 (ja) * 2004-01-28 2012-01-11 ホソカワミクロン株式会社 ナノ粒子含有組成物およびその製造方法
ES2246695B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
KR101323540B1 (ko) * 2007-02-07 2013-10-29 사이단호진한다이비세이부쯔뵤우겐큐우카이 암의 치료제
AU2008231424A1 (en) * 2007-03-28 2008-10-02 National Institute Of Immunology Polymer particles based vaccine
EP3179985A1 (de) 2014-08-14 2017-06-21 Brown University Zusammensetzungen zur stabilisierung und ausgabe von proteinen
EP3215192B1 (de) * 2014-11-05 2021-02-17 Selecta Biosciences, Inc. Verfahren und zusammensetzungen in zusammenhang mit synthetischen nanocarriern mit rapamycin in einem stabilen übersättigten zustand
GB201918963D0 (en) 2019-12-20 2020-02-05 Provost Fellows Scholars And Other Members Of Board Of Trinity College Dublin Polymeric nanoparticles as vaccine adjuvants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines

Also Published As

Publication number Publication date
AU5441299A (en) 2000-03-21
ATE322285T1 (de) 2006-04-15
EP1107783A1 (de) 2001-06-20
CA2341358C (en) 2011-04-26
EP1107783B1 (de) 2006-04-05
JP2002523471A (ja) 2002-07-30
CA2341358A1 (en) 2000-03-09
WO2000012125A1 (en) 2000-03-09
JP4526708B2 (ja) 2010-08-18
CA2731995C (en) 2013-05-28
CA2731995A1 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
DE69930753D1 (de) Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ATE223702T1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
DE69929444D1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
ES2156199T3 (es) Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.
ATE343396T1 (de) Immunverstärkende zusammensetzung in fester verabreichungsform mit kollagen oder polydimethylsiloxan als trägersubstanzen
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
DE69511379T2 (de) Immunogens gegen gonadotropin releasing hormone
AR003464A1 (es) Método para la producción de una composición apropiada para el uso en composiciones cosméticas que comprende un absorbente de uv orgánico insoluble micronizado.
AUPR011700A0 (en) Composition comprising immunogenic virus sized particles (VSP)
EP0558631A4 (en) Recombinant avirulent salmonella antifertility vaccines
ES8500997A1 (es) Un metodo para producir un peptido.
IL106968A0 (en) Potentiation of immunogenic response
DE69620271D1 (de) Polyribosylribitol-phosphat enthaltende Haemophilus-influenzae-Typ-b-Impfstoffzubereitung und Verfahren zur deren Herstellung
MXPA04001509A (es) Particulas de fosfato de calcio como coadyuvantes para la mucosa.
BR0212556A (pt) interleucina-12 como um adjuvante de vacina veterinária
MY125000A (en) Novel compositions
ATE460943T1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
ATE364395T1 (de) Konjugat-impfstoffe zur vorbeugung der zahnkaries
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
DE69941848D1 (de) Orale impfstoff-zusammensetzung
WO1997047271A3 (en) Cellular vaccines and immunotherapeutics and methods for their preparation
ES2126619T3 (es) Procedimiento de preparacion de biotina.

Legal Events

Date Code Title Description
8332 No legal effect for de